[
    {
        "file_name": "Exhibit 10.13 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. DATED: OCTOBER 15, 2009 PACIRA PHARMACEUTICALS, INC. and EKR THERAPEUTICS, INC. AMENDED AND RESTATED STRATEGIC LICENSING, DISTRIBUTION AND MARKETING AGREEMENT",
        "perturbation": [
            {
                "type": "Inconsistencies - Legal Contradiction",
                "original_text": "\"Applicable Laws\" Shall mean all laws, rules and regulations regarding the manufacture, packaging, labeling, import, export, storage, distribution, representation, promotion, marketing and sale of the Products including but not limited to the Federal Food, Drug and Cosmetic Act of 1938, as amended (\"FD&C Act\") and the Controlled Substances Act, as amended (21 U.S.C. §801 et seq.), or as defined in attendant regulations promulgated under authorities granted by the FD&C Act, together with any equivalent laws, rules, regulations, codes or guidelines having effect in any jurisdiction in the Territory;",
                "changed_text": "\"Applicable Laws\" Shall mean some laws, rules and regulations regarding the manufacture, packaging, labeling, import, export, storage, distribution, representation, promotion, marketing and sale of the Products including but not limited to the Federal Food, Drug and Cosmetic Act of 1938, as amended (\"FD&C Act\") and the Controlled Substances Act, as amended (21 U.S.C. §801 et seq.), or as defined in attendant regulations promulgated under authorities granted by the FD&C Act, together with some equivalent laws, rules, regulations, codes or guidelines having effect in any jurisdiction in the Territory;",
                "explanation": "By modifying “all laws” to “some laws”, this introduces ambiguity and contradiction. It is now unclear whether the contract intends to comply with all or only a portion of applicable laws. This creates a legal contradiction, as companies must adhere to *all* relevant regulations.",
                "contradicted_law": "Federal Food, Drug, and Cosmetic Act",
                "law_citation": "21 U.S.C. § 321",
                "law_url1": [
                    "https://www.fda.gov/regulatory-information/laws-enforced-fda/federal-food-drug-and-cosmetic-act-fdc-act"
                ],
                "law_url2": [
                    "https://uscode.house.gov/view.xhtml?req=granuleid%3AUSC-prelim-title21-chapter9&edition=prelim"
                ],
                "law_explanation": "The FD&C Act mandates adherence to *all* applicable regulations concerning the safety, manufacturing, and distribution of drugs. By stating that only *some* laws apply, the modified contract directly contradicts this requirement, creating an unenforceable and non-compliant provision.",
                "location": "Section 1.1"
            },
            {
                "type": "Inconsistencies - Legal Contradiction",
                "original_text": "During the Term, PPI shall at its own cost and expense take all actions necessary to comply with all Applicable Laws and obtain and maintain all necessary license, permits, records and authorizations PPI is required to obtain and maintain hereunder so as to enable PPI to perform its obligations hereunder and under the Supply Agreement so as to enable EKR to fully exercise the Distribution Rights.",
                "changed_text": "During the Term, PPI shall at its own cost and expense take commercially reasonable actions to comply with most Applicable Laws and obtain and maintain most necessary licenses, permits, records and authorizations PPI is required to obtain and maintain hereunder so as to enable PPI to perform its obligations hereunder and under the Supply Agreement so as to enable EKR to fully exercise the Distribution Rights.",
                "explanation": "The original text mandates that PPI comply with *all* Applicable Laws. The changed text modifies this to “commercially reasonable actions to comply with most Applicable Laws.” This introduces ambiguity, as it is now unclear which laws PPI must comply with and introduces a subjective standard.",
                "contradicted_law": "The Controlled Substances Act",
                "law_citation": "21 U.S.C. § 841",
                "law_url1": [
                    "https://www.dea.gov/drug-information/csa"
                ],
                "law_url2": [
                    "https://uscode.house.gov/view.xhtml?req=granuleid%3AUSC-prelim-title21-chapter13&edition=prelim"
                ],
                "law_explanation": "The CSA requires strict compliance with *all* its provisions regarding the handling, distribution, and dispensing of controlled substances. Modifying the contract to only require compliance with “most Applicable Laws” directly contradicts this requirement.",
                "location": "Section 3.17"
            },
            {
                "type": "Inconsistencies - Legal Contradiction",
                "original_text": "Any discounts, rebates, or promotional allowances/incentive programs provided are \"discount[s] or other reduction[s] in price\" for purposes of 42 U.S.C. Section 1320a-7b(b)(3)(A) and may be subject to the reporting requirements under state and federal Medicaid and Medicare laws.",
                "changed_text": "Any discounts, rebates, or promotional allowances/incentive programs provided may or may not be \"discount[s] or other reduction[s] in price\" for purposes of 42 U.S.C. Section 1320a-7b(b)(3)(A) and may be subject to the reporting requirements under state and federal Medicaid and Medicare laws.",
                "explanation": "By introducing “may or may not be”, this creates uncertainty as to whether discounts and rebates are subject to anti-kickback statute reporting requirements. This contradicts the strict guidelines on remuneration under those programs.",
                "contradicted_law": "The Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b))",
                "law_citation": "42 U.S.C. § 1320a-7b(b)",
                "law_url1": [
                    "https://uscode.house.gov/view.xhtml?req=granuleid%3AUSC-prelim-title42-section1320a-7b"
                ],
                "law_url2": [
                    "https://oig.hhs.gov/fraud/anti-kickback-statute/index.asp"
                ],
                "law_explanation": "This statute makes it a criminal offense to knowingly and willfully offer, pay, solicit, or receive any remuneration to induce or reward referrals of items or services reimbursable by a Federal health care program. By making it uncertain whether discounts must be reported, the contract undermines compliance with this law.",
                "location": "Section 4.20"
            }
        ]
    }
]